Update: June 2023
|
ACH |
Air change per hour |
|
AFB |
Acid-fast bacilli |
| ALT | Alanine aminotransferase |
|
Am |
Amikacin |
|
Amx/Clv |
Amoxicillin/clavulanic acid |
|
ART |
Antiretroviral therapy |
|
ARV |
Antiretroviral |
| AST | Aspartate aminotransferase |
|
BCG |
Bacillus Calmette-Guérin |
|
Bdq |
Bedaquiline |
| BPNS | Brief peripheral neuropathy screen |
| BSC | Biosafety cabinet |
|
CDC |
Centers for Disease Control and Prevention |
|
Cfz |
Clofazimine |
|
CrCl |
Creatinine clearance |
|
CMX |
Cotrimoxazole |
| CNS | Central nervous system |
|
CPC |
Cetylpyridinum chloride |
|
CPT |
Cotrimoxazole preventive therapy |
|
Cs |
Cycloserine |
| CSF | Cerebrospinal fuid |
|
CXR |
Chest x-ray |
| Dlm | Delamanid |
|
DOT |
Directly observed therapy |
|
DR |
Drug resistance |
|
DR-TB |
Drug-resistant tuberculosis |
| DS-TB | Drug-susceptible tuberculosis |
|
DST |
Drug susceptibility test |
|
E |
Ethambutol |
|
ECG |
Electrocardiogram |
|
EPTB |
Extrapulmonary tuberculosis |
|
Eto |
Ethionamide |
|
FDC |
Fixed-dose combination |
|
FNA |
Fine needle aspiration |
|
FQ |
Fluoroquinolone |
| gDST | Genotypic drug susceptibility test |
| GUV | Germicidal ultraviolets |
|
H |
Isoniazid (standard dose) |
| HbA1c | Glycated haemoglobin |
| Hh | Isoniazid (high dose) |
|
HIV |
Human immunodeficiency virus |
|
HPF |
High-power field |
| Hr | Isoniazid resistance |
| Hr-TB | Isoniazid resistant tuberculosis |
| IGRA |
Interferon gamma release assay |
|
IPC |
Infection prevention and control |
|
IM |
Intramuscular |
|
Imp/Cln |
Imipenem/cilastatin |
| INI | Integrase inhibitor |
|
IRIS |
Immune reconstitution inflammatory syndrome |
| IV | Intravenous |
| LF-LAM | Lateral flow urine lipoarabinomannan assay |
|
LFT |
Liver function test |
|
Lfx |
Levofloxacin |
|
LPA |
Line probe assay |
| LTBI | Latent tuberculosis infection |
| LTR | Long treatment regimen |
|
Lzd |
Linezolid |
|
MDR |
Multidrug resistance |
|
MDR-TB |
Multidrug-resistant tuberculosis |
|
Mfx |
Moxifloxacin (standard dose) |
|
Mfxh |
Moxifloxacin (high dose) |
|
Mpm |
Meropenem |
| MTB | Mycobacterium tuberculosis |
| NAAT | Nucleic acid amplification test |
| NGS | Next generation sequencing |
|
NNRTI |
Non-nucleoside reverse transcriptase inhibitor |
|
NRTI |
Nucleoside reverse transcriptase inhibitor |
| P | Rifapentine |
| Pa | Pretomanid |
|
PAS |
Para-aminosalicylic acid |
|
PCP |
Pneumocystosis |
|
PCR |
Polymerase chain reaction |
| pDST | Phenotypic drug susceptibility test |
|
PI |
Protease inhibitor |
|
PO |
Orally (per os) |
| PTB | Pulmonary tuberculosis |
|
Pto |
Prothionamide |
|
R |
Rifampicin |
|
Rfb |
Rifabutin |
| RMT | Rapid molecular test |
|
RR |
Rifampicin resistance |
|
S |
Streptomycin |
| SAT | Self-administered treatment |
| STR | Short treatment regimen |
|
TB |
Tuberculosis |
| tNGS | Targeted next generation sequencing |
| Trd | Terizidone |
|
TSH |
Thyroid-stimulating hormone |
|
TST |
Tuberculin skin test |
| ULN | Upper limit of normal |
| VVS | Ventilated workstation |
| WGS | Whole genome sequencing |
|
WHO |
World Health Organization |
|
XDR |
Extensive drug resistance |
|
XDR-TB |
Extensively drug-resistant tuberculosis |
|
Z |
Pyrazinamide |